Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
复制标题
DOI：
10.1007/s12250-020-00270-x
复制
发表时间：
2020-07-23
影响因子：
5.5
通讯作者：
Liu, Man-Qing
中科院分区：
文献类型：
--
作者：
Kong, Wen-Hua;Zhao, Rong;Liu, Man-Qing
冠状病毒病2019(新冠肺炎)全球大流行造成的巨大患者数量促使人们更多地了解其免疫学特征，包括基本免疫参数的概况。本研究收集了2020年1月至2月武汉市报告的88例新冠肺炎患者，其中重度/危重患者32例，轻中度患者56例。平均年龄56.43岁(17-83岁)，性别比为43：45。用商品化试剂盒检测SARS-CoV-2RNA，用磁粒子化学发光免疫分析法检测SARS-CoV-2血清中抗SARS-CoV-2(SARS-CoV-2)抗体水平，并将血清学检测结果与核酸检测结果进行比较。88例患者中，NAT与抗体联合检测阳性率为95.45%，显著高于单一核酸检测(73.86%)和血清学检测(65.91%)(P<；0.001)。然后分析时间分布与抗体应答水平的相关性。结果表明，患者发病后第5天开始血清转换，且血清免疫球蛋白升高早于免疫球蛋白M。不同疾病严重程度的患者之间的比较表明，早期血清转换和高抗体滴度与较轻的临床症状有关。这些结果支持血清学检测和NAT联合用于新冠肺炎的常规诊断，并为不同疾病严重程度患者的抗体应答时间谱提供了证据。
The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.